**Supplementary Table 1.** **The four noninvasive scoring systems for detecting fibrosis13-16**

|  |  |  |  |
| --- | --- | --- | --- |
| **Formula** | **Equation** | **Low cutoff** | **High cutoff** |
| APRI | ([AST/upper limit of normal]/platelet count [109/L])×100 | 0.5 | 1.5 |
| BARD | BMI ≥28 kg/m2= 1 point  AST/ALT ≥0.8= 2 points  Diabetes= 1 point  (Range: 0-4) | 2 | |
| FIB-4 | (Age [years]×AST [IU/L])/ (platelet count [109/L]×) | 1.3 | 2.67 |
| 1.45 | 3.25 |
| NFS | -1.675+0.037×age (years) + 0.094×BMI (kg/m2)+1.13×intermitent fasting glucose/diabetes (yes= 1, no= 0)+0.99×AST/ALT-0.013×platelet count (109/L)-0.66×albumin (g/dL) | -1.455 | 0.676 |

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index.

**References**

[13] Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38(2):518-526. doi: 10.1053/jhep.2003.50346, PMID: 12883497.

[14] Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008;57(10):1441-1447. doi: 10.1136/gut.2007.146019, PMID: 18390575.

[15] Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43(6):1317-1325. doi: 10.1002/hep.21178, PMID: 16729309.

[16] Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45(4):846-854. doi: 10.1002/hep.21496, PMID: 17393509.